TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women with a T-score ≤ -1.5 SD and at least one osteoporosis related vertebral fracture. Chronic back pain.~Exclusion Criteria:~* Previous/current treatment and medical history.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTH (1-84) (Type: ACTIVE_COMPARATOR): PTH (1-84) + placebo alendronate
- Alendronate (Type: ACTIVE_COMPARATOR): PTH (1-84) placebo + alendronate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients developing or developed acute or chronic GVHD within the last 10 days which require systemic immunosuppressive therapy of corticosteroids with- or-without other immunosuppressive agents including calcineurin inhibitors.~  1. acute GVHD, grade 2-4~ 2. chronic GVHD, mild grade with high risk or moderate to severe grade~* Written informed consent form~Exclusion Criteria:~* Aspartate transaminase or alanine transaminase level \> 10 times UNL or Bilirubin or alkaline phosphatase level \> 5 times UNL~* Active or chronic hepatitis virus B or C infection requiring antiviral therapy~* Estimated life expectancy \< 30 days~* History of allergy, sensitivity, or any serious reaction to itraconazole oral solution~* Previous history of Zygomycosis~* Evidence of active fungal disease including high galactomannan titer above 0.5, within 2 weeks.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- itraconazole, prophylaxis, Oral solution (Type: EXPERIMENTAL): For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: DEFINED_POPULATION
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>= 18 years old~* PAD~* Chronic Critical Limb Ischemia~* requiring surgical intervention~* able to give informed consent~Exclusion Criteria:~* emergent/urgent requirement for surgical intervention~* requiring surgical intervention due to acute traumatic injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral spastic cerebral palsy~* Gross Motor Function Classification Scale (GMFCS) II-IV~Exclusion Criteria:~* Prior orthopedic surgery on the lower extremity or the trunk (\<6 months)~* Prior neurosurgical interventions (\<6 months)~* Significant mental retardation~* Severe contractures~* Prior Lokomat training (\<6 months)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Lokomat training (Type: EXPERIMENTAL): Lokomat training
- Waiting list (Type: OTHER): Lokomat training after waiting phase of 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~For patients with CLL:~• Confirmed diagnosis of chronic lymphocytic leukemia (CLL)~For patients with NHL:~* Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL).~* Must have a site of disease amenable to biopsy, and be suitable and willing to undergo study required biopsies at screening and during therapy.~Exclusion Criteria, applicable to both CLL and NHL:~* History of anaphylactic or other severe hypersensitivity/infusion reactions to ADCs, monoclonal antibodies (mAbs) and/or their excipients such that the patient in unable to tolerate immunoglobulin/monoclonal antibody administration~* Any prior history of treatment with maytansine (DM1 or DM4)-based ADC~* Known intolerance to a maytansinoid~* Patients with any active or chronic corneal disorders~* Patients who have any other condition that precludes monitoring of the retina or fundus~* Patients with active CNS involvement are excluded, except if the CNS involvement has been effectively treated and provided that local treatment was completed \>4 weeks before first dose of study treatment. Patients that have been effectively treated for CNS disease and are stable under systemic therapy may be enrolled provided all other inclusion and exclusion criteria are met. Patients who received prophylactic intrathecal treatment are eligible, if treatment discontinued \>5 half-lives prior to the first dose of study treatment~* Impaired cardiac function or clinically significant cardiac disease~* Known history of Human Immunodeficiency Virus (HIV) infection~* Active HBV or HCV infection. Patients whose disease is controlled under antiviral therapy should not be excluded. Patients who are anti-HBcAb positive should be HBsAg negative and HBV-DNA negative to be eligible~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JBH492 single agent (Type: EXPERIMENTAL): Patients with R/R CLL or NHL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Agents and Cholesterol Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 40-70, osteoarthritis, male or female~Exclusion Criteria:~* other known autoimmune or inflammatory rheumatic conditions, renal disease, current or recent (\>1 month) corticosteroid or statin treatment, contraindications to medication (i.e. those taking oral anticoagulants, e.g. warfarin), those pregnant or trying to become pregnant or breastfeeding. Participants will not have consumed any medications containing aspirin or other NSAIDs for at least 2 weeks before the trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- naproxen (Type: None): Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
- diclofenac (Type: None): Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
- celecoxib (Type: None): Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Focal Intraoperative Radiotherapy of Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Histologically confirmed diagnosis of invasive cancer in the presence of up to 10 lesions suggestive of BM~* Indication of resection of single lesion suggestive of BM and evidence of macroscopic complete resection~* Patient consent to participate in the study~Exclusion Criteria:~* Previous cranial radiotherapy~* Any kind of antineoplasic systemic treatment for less than 7 days of the procedure~* Cavities with proximity \< 10 mm from the brainstem or optical pathway.~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraoperative Radiotherapy (Type: EXPERIMENTAL): Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Statin Eligibility Prior to Myocardial InfarCtion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults admitted with MI, age 30 to 75~* known lipid profile~Exclusion Criteria:~* on statin before enrollment

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cystic Fibrosis and Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 18 years or older~* Diagnosis of CF~* Self-reported UI (at least answer of a little on King's Health Questionnaire - Question #2)~* Fluent in spoken English~* Ability to present for in-office exam and study procedures~Exclusion Criteria:~* Age \<18 years~* No UI~* Inability to comply with study protocol~* No diagnosis of Cystic Fibrosis~* Pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- disposable urethral support device (Type: ACTIVE_COMPARATOR): disposable urethral support device
- Reusable Underwear (Type: ACTIVE_COMPARATOR): Reusable Underwear
- pelvic floor muscle therapy (PFMT) (Type: ACTIVE_COMPARATOR): Pelvic floor muscle therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-64 years of age;~* ambulatory;~* influenza-like illness;~* positive rapid assay for detection of influenza antigen.~Exclusion Criteria:~* presentation \>36h after onset of symptoms;~* influenza-like symptoms outside an outbreak based on local surveillance activities;~* influenza vaccination between November 2006 and January 2007;~* receipt of antiviral therapy, systemic steroids or immunosuppressants within 2 weeks prior to study day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Digital Behavioral Therapy for Sleep Problems

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-5 diagnosis of insomnia disorder~* Aged 18 years or older~* Reliable Internet access using either computer or smartphone~* Ability to read and understand English~Exclusion Criteria:~* High risk of obstructive sleep apnea~* Diagnosis of restless legs syndrome~* Severe health issues requiring hospital admission~* Currently receiving psychological treatment for insomnia~* Reporting current suicidal ideation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Digital cognitive-behavioral therapy for insomnia (dCBTI) (Type: EXPERIMENTAL): Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions
- Sleep hygiene education (SHE) (Type: ACTIVE_COMPARATOR): Recognized and commonly prescribed set of sleep hygiene instructions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vertebroplasty In The Treatment Of Acute Fracture Trial - The VITTA Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Presence of:~* at least one and at most two acute VCF (\< 6 weeks) at levels caudate to T4, confirmed with physical examination and radiographic imaging~* if timing of the fracture is unclear, the following criteria are required for inclusion in the trial~  1. an MRI scan showing edema at the fracture level(s) or~ 2. a bone scan showing increased uptake~* Physical examination showing axial back pain likely secondary to the VCF with restricted mobilization (score not maximum on any one of the following Barthel's Index items: transfer, mobility, bathing, dressing, stairs and toilet use)~* French or English speaking patient willing to return for follow-up or capable of following up with phone interviews if needed~Exclusion Criteria:~* Recent (\<30 days) major surgery causing debilitating pain~* Coagulopathy or thrombocytopenia precluding interventional treatment~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Percutaneous vertebroplasty (PV) (Type: EXPERIMENTAL): The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
- Facet block (Type: ACTIVE_COMPARATOR): injection of anti-inflammatory and analgesic drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Asian full-term neonates with jaundice between 48 and 96 hours of age.~Exclusion Criteria:~* Patients with low-birth-weight, early onset jaundice before 48 hours of age, perinatal asphyxia, antimicrobial therapy or respiratory disorders. Patients with jaundice caused by hemolysis, or functional or anatomic obstruction. Patients who need treatments except for phototherapy.

- Gender: ALL
- Minimum Age: 2 Days
- Maximum Age: 4 Days
- Healthy Volunteers: f

Study Arms:
- High level irradiation (Type: ACTIVE_COMPARATOR): High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
- Low level irradiation (Type: EXPERIMENTAL): Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* planned allogenic stem cell transplantation~* patient mentally and intellectually able to understand and sign the form~Exclusion Criteria:~* Current enrollment in another intervention study~* clinical diagnosis of depression by HADS-D score plus drug therapy for depression at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Interventions:~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks
- Control Group (Type: NO_INTERVENTION): control group. No interventions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 to 40 years of age~* Have a body mass index 25-40 kg/m2~* Have a sedentary lifestyle (participated in less than 30 minutes of physical activity 3 days per week over the last 6 months)~* History of irregular menstrual cycles (fewer than 6 cycles in past year)~* Excess androgen (to be measured at screening)~* Willing to supplement normal diet with cinnamon extract and a placebo for 12 weeks~* You can stay overnight at Pennington Center three times over the next six months~Exclusion Criteria:~* Do not meet our diagnostic criteria for polycystic ovary syndrome~* Have heart disease, lung disease, liver disease, blood disease, kidney disease, type 1 or 2 diabetes, or any other disease that in the opinion of the doctor might make you ineligible.~* Have cancer (active malignancy with or without concurrent chemotherapy).~* Abuse alcohol or illegal drugs.~* Smoke or have smoked within the previous 6 months. No smoking will be permitted during the study.~* Have donated blood within 30 days prior to randomization date.~* Have a hemoglobin, hematocrit, red blood cell, or iron level below the normal lower limit at screening.~* Taking medications that alter your glucose metabolism, (30 minute or more, 4 or more times per week over the past year.)~* Unwilling or unable to adhere to the clinical evaluation schedule over the entire six-month follow-up period.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Cinnamon Supplementation (Type: ACTIVE_COMPARATOR): A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E\> 20:1) will be consumed before meals, three times per day.
- Placebo (Type: PLACEBO_COMPARATOR): A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Primary diagnosis of adenocarcinoma of the colon or rectum and meeting one of the following risk criteria during the primary surgery: Perforated bowel (spontaneous or not) Occlusion Peritoneal deposits Invasion of serosa of more than 4 cm diameter Concurrent ovarian metastases Randomization eligibility: Presence of proven recurrent peritoneal disease (only one micronodule of 1 mm sufficient) at second look laparotomy Total resection of macroscopic lesions possible (local recurrence, lymph node or hepatic metastases)~PATIENT CHARACTERISTICS: Age: 70 and under Performance status: Not specified Life expectancy: Not specified Hematopoietic: WBC at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.4 mg/dL Cardiovascular: No cardiac condition that would increase surgical risk Pulmonary: No pulmonary condition that would increase surgical risk Other: No other condition that would increase surgical risk No other malignancy within the past 5 years except basal cell skin cancer~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy Radiotherapy: No concurrent anticancer radiotherapy Surgery: See Disease Characteristics

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues